Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1603-1614

  Dudek Perić, Aleksandra M ^a   Ferreira, Gabriela B ^a   Muchowicz, Angelika ^b   Wouters, Jasper ^c   Prada, Nicole ^d   Martin, Shaun ^a   Kiviluoto, Santeri ^e   Winiarska, Magdalena ^b   Boon, Louis ^f   Mathieu, Chantal ^a   Van Den Oord, Joost ^c   Stas, Marguerite ^a   Gougeon, Marie Lise ^d   Golab, Jakub ^b,g   Garg, Abhishek D ^a   Agostinis, Patrizia ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^d INSTITUT PASTEUR   (France)

^e LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^f BIOCEROS   (Netherlands)

^g INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CALRETICULIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; REACTIVE OXYGEN METABOLITE; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR; ALKYLATING AGENT; AUTACOID; CYTOKINE; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATORY CELL; LIMB PERFUSION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY; TUMOR IMMUNITY; TUMOR REJECTION; UPREGULATION; ANIMAL; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SKIN NEOPLASMS;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CALRETICULIN; CELLS, CULTURED; CYTOKINES; ENDOPLASMIC RETICULUM STRESS; HUMANS; INFLAMMATION MEDIATORS; MELANOMA; MELPHALAN; MICE; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS;

EID: 84934317844     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2089     Document Type: Article

References (49)

1. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013; 39: 355-67.
2. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
3. Adams S, O'Neill DW, Nonaka D, Hardin E., Chiriboga L, Siu K, et al Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181: 776-84.
4. Kitano S, Tsuji T, Liu C., Hirschhorn-Cymerman D, Kyi C, Mu Z., et al. Enhancement of tumor-reactive cytotoxic CD4 T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 2013; 1: 235-44.
5. Dudek AM, Garg AD, Krysko D.V., De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24: 319-33.
6. Coussens LM, Zitvogel L, Palucka AK Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
7. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-28.
8. Garg AD, Martin S, Golab J., Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21: 26-38.
9. Obeid M, Tesniere A, Ghiringhelli F., Fimia GM, Apetoh L, Perfettini JL, et al Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
10. Fucikova J, Kralikova P, Fialova A., Brtnicky T, Rob L, Bartunkova J., et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-33.
11. Ghiringhelli F, Apetoh L, Tesniere A., Aymeric L, Ma Y, Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8.
12. Apetoh L, Ghiringhelli F, Tesniere A., Obeid M, Ortiz C, Criollo A., et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
13. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-8.
14. Qin Y, Han Y, Cao C., Ren Y, Li C, Wang Y. Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice. Cancer Biol Ther 2011; 11: 574-80.
15. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F., Roux S, Chaput N, et al Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701.
16. Kroemer G, Galluzzi L, Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
17. White J, Mamounas E. Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol 2014; 32: 494-5.
18. Whelan T, Levine M. More evidence that locoregional radiation therapy improves survival: what should we do? J Natl Cancer Inst 2005; 97: 82-4.
19. Garg AD, Nowis D, Golab J., Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010; 15: 1050-71.
20. Turley RS, Raymond AK, Tyler DS Regional treatment strategies for intransit melanoma metastasis. Surg Oncol Clin N Am 2011; 20: 79-103.
21. Shetty G, Beasley GM, Sparks S, Barfield M., Masoud M, Mosca PJ, et al Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol 2013; 20: 1128-35.
22. Nieweg OE, Kroon BB Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 2014; 109: 332-7.
23. Bulman AS, Jamieson CW Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980; 67: 660-2.
24. Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005; 65: 4300-8.
25. Buytaert E, Matroule JY, Durinck S, Close P., Kocanova S, Vandenheede JR, et al Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 2008; 27: 1916-29.
26. Ferreira GB, van Etten E, Lage K, Hansen DA, Moreau Y, Workman CT, et al. Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D. Proteomics 2009; 9: 3752-64.
27. Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol 2014; 192: 4210-20.
28. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A., Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-79.
29. Garg AD, Dudek AM, Ferreira G.B., Verfaillie T., Vandenabeele P, Krysko DV, et al ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9: 1292-307.
30. Wachowska M, Gabrysiak M, Muchowicz A., Bednarek W, Barankiewicz J, Rygiel T., et al. 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer 2014; 50: 1370-81.
31. Wouters J, Stas M, Govaere O., Van den Eynde K, Vankelecom H, van den Oord JJ. Gene expression changes in melanoma metastases in response to high-dose chemotherapy during isolated limb perfusion. Pigment Cell Melanoma Res 2012; 25: 454-65.
32. Peters LR, Raghavan M. Endoplasmic reticulum calcium depletion impacts chaperone secretion, innate immunity, and phagocytic uptake of cells. J Immunol 2011; 187: 919-31.
33. Lee YY, Hong SH, Lee Y.J., Chung SS, Jung HS, Park SG, et al Taurourso-deoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress. Biochem Biophys Res Commun 2010; 397: 735-9.
34. Park GB, Kim YS, Kim D, Kim S, Lee HK, Cho DH, et al. Melphalan-induced apoptosis of EBV-transformed B cells through upregulation of TAp73 and XAF1 and nuclear import of XPA. J Immunol 2013; 191: 6281-91.
35. Panaretakis T, Kepp O, Brockmeier U., Tesniere A, Bjorklund AC, Chapman D.C., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-90.
36. Spisek R, Charalambous A, Mazumder A., Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109:4839-45.
37. Garg AD, Dudek AM, Agostinis P. Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A. Cell Death Dis 2013; 4: e826.
38. Martins I, Kepp O, Schlemmer F., Adjemian S, Tailler M, Shen S., et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58.
39. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63: ii84-ii89.
40. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-99.
41. de Wilt J.H., ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-3.
42. Dudek AM, Martin S, Garg A.D., Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2013; 4: 438.
43. D'Eliseo D., Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones 2013; 18: 801-8.
44. Herr W, Ranieri E, Olson W., Zarour H, Gesualdo L, Storkus WJ Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96: 1857-64.
45. Buytaert E, Callewaert G, Hendrickx N., Scorrano L, Hartmann D, Missiaen L., et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J 2006; 20: 756-8.
46. Zappasodi R, Pupa SM, Ghedini G.C., Bongarzone I., Magni M, Cabras AD, et al Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70: 9062-72.
47. Hausner PF. Image-guided thermal ablation of tumor increases the plasma level of interleukin-6 and interleukin-10: is plasma level of interleukin-6 a surrogate for immunogenic cell death? J Vasc Interv Radiol 2013; 24: 1112-3.
48. Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003; 4: 359-64.
49. Denmeade SR, Mhaka AM, Rosen D.M., Brennen WN, Dalrymple S, Dach I, et al Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4: 140ra86.